Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
RSV, Pfizer and FDA
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how much advantage will be gained from the nod as the Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in the wider age group.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
RSV Vaccine Tied to Fewer Hospitalizations, ED Visits in Older, High-Risk Adults
The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) visits in older patients during the first season of the vaccine's rollout, according to a retrospective analysis.
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
RSV, Covid and tripledemic
Covid XEC, flu and RSV 'tripledemic' to hit UK - symptoms to watch out for
Health experts are warning of a potential 'tripledemic' this winter - here's how to spot the early symptoms of flu, RSV and covid, and how they differ from each other
Covid, flu and RSV symptoms and differences amid UK 'tripledemic' threat
The NHS has listed the symptoms of covid, RSV and flu to help you tell the difference between each one, as cases forecast to surge
COVID-19 XEC Variant: Symptoms to Watch for as Virus Surges
A new coronavirus virus variant, XEC, is rapidly spreading across the United States. XEC has become the second most prevalent strain in the country, according to data released by the U.S. Centers for Disease Control and Prevention (CDC),
22h
on MSN
Pneumonia can be a deadly complication of COVID, the flu, and RSV. What to know about pneumococcal vaccination
Respiratory virus season has arrived, and hopefully you’re up to date on vaccinations that can help prevent infectious ...
4d
Study confirms RSV vaccine's protective power for seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...
ConsumerAffairs
7d
RSV gets no respect although it is a common virus and can be severe
RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren ...
5d
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
Medpage Today on MSN
3d
Novel Monoclonal Antibody Protects Infants Against RSV
Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...
6h
on MSN
Doctor clears up confusion over Covid, flu and RSV jabs as cases rise
Up to 10,000 Brits a day are getting a new variant of coronavirus called XEC, which is a mixture of the Delta and Omicron ...
dermatologyadvisor
23h
Investigational RSV Vaccine mRNA-1345: Revaccination Safe in Eligible Older Adults
Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...
cidrap.umn
1d
Genomic surveillance tracks RSV evolution, identifies mutations in Minnesota
A new study shows that the addition of respiratory syncytial virus (RSV) to Minnesota’s viral genomic surveillance program ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Pfizer
Abrysvo
Merck
clesrovimab
COVID-19
Feedback